Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-09
2007-10-09
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S300000, C544S279000, C546S122000
Reexamination Certificate
active
11116310
ABSTRACT:
The inventive subject matter relates to compounds, pharmaceutical compositions, and kits containing a heterocyclic compound represented by the formula (I)wherein R is an alkyl group optionally having substituent(s) etc., X is an amino group optionally having substituent(s), Y1and Y2are nitrogen atoms etc., an isomer or solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient.
REFERENCES:
patent: 61-060687 (1986-03-01), None
patent: 11-222486 (1999-08-01), None
patent: WO 02/088122 (2002-11-01), None
Merck Index, 9thEd., 1976, p. Fl-8.
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry, pp. 212-228, in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons.
Gibson, “Increased gut permeability on Crohn's disease: is TNF the link?” Gut, 2004: 53, 1724-25.
Giamarellos-Bouboulis, et al., Effective Immunomodulatory Treatment ofEscherichia coliExperimental Sepsis with Thalidomide, Antimicrobial Agents and Chemotherapy, Aug. 2003, p. 2445-2449.
“Access to Anti- TNF-α Therapies for Adults with Inflammatory Arthritis,” Implementation of NICE Guidance on use of Anti-TNF-α Therapies for Adults with Rheumatoid Arthritis, Jun. 2005, pp. 1-8, the NICE Report.
Waldman, “Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases,” Arthritis Research & Therapy, vol. 6, No. 4, 2004, pp. 174-177.
Jiménez, “Infliximab in the Treatment of Severe Ulcerative Colitis,” Rev. esp. enfirm. Dig., vol. 2004, No. 2, Feb. 2004, 4 pages.
Medical dictionary, University of Newcastle upon Tyne, http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=prophylaxis&action=Search+OMD, 2005.
Understanding Animal Research in Medicine, Aug. 2004, http://www.rds-online.org.uk/pages/page.asp?i—PageID=141&l—ToolbarID=3.
.Waterston, et al., Cancer Therapy, vol. 2, pp. 131-148, 2004.
Elnagdi, M.H. et al. “Activated Nitriles in Heterocyclic Synethsis: A New Procedure for the Synthesis of Pyrimidine Derivatives”,J. Chem. Soc. Perkin Trans., vol. I pp. 2667-2670, 1982.
Chujo Yoshitomo
Fujita Kohichi
Fukuda Shunsuke
Ikenoue Yuka
Murata Masahiro
Ajinomoto Co. Inc.
Berch Mark L.
Hopkins Susanne M.
Jaisle Cecilia M
Nath Gary M.
LandOfFree
Heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3903031